Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

This study has been completed.

Study NCT00161954. Last updated on October 19, 2006. Information provided by Baxter Healthcare Corporation

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Official Title ^†

Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Brief Summary

The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.

Detailed Description

Study Phase

Phase IV

Study Type ^†

Interventional

Study Design ^†

Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Primary Outcome Measure ^†

Secondary Outcome Measure ^†

Condition ^†

Encephalitis, Tick-Borne

Intervention ^†

Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

MEDLINE PMIDs

Links

Recruitment Information Fields

Recruitment Status ^†

Completed

Enrollment ^†

Start Date ^†

March 2004

Completion Date

May 2004

Eligibility Criteria ^†

Inclusion Criteria:

Understanding the nature of the study, agreement to its provisions and written informed consent
Written informed consent of subject´s parents / legal guardians (if subject is under 18 years of age)
Aged >= 16 years (from the 16th birthday) to <= 65 years (to the last day before the 66th birthday)
Clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial)
Negative pregnancy test result at the first medical examination (if female and capable of bearing children)
Agreeing to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
Agreeing to keep a subject diary.

Exclusion Criteria:

History of any previous TBE vaccination
History of TBE infection
History of infection with other flaviviruses
History of vaccination against yellow fever and/or Japanese B-encephalitis
History of allergic reactions, in particular to one of the components of the vaccine
Suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
Known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
Donation of blood or plasma within one month of study start
Having received a blood transfusion or immunoglobulins within one month of study entry
HIV positivity (an HIV test is not required specifically for the purpose of this study
Simultaneous participation in another clinical trial including administration of an investigational product
Participating in any other clinical study within six weeks prior to study start
Participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies)
Pregnancy or lactation (if female)
Having received any other vaccination within two weeks prior to study entry

Gender

Both

Ages

16 Years to 65 Years

Accepts Healthy Volunteers

Yes

Contacts ^††

Location Countries ^†

Belgium

Administrative Information Fields

NCT ID ^†

NCT00161954

Organization ID

225

Secondary IDs ^††

Study Sponsor ^†

Baxter Healthcare Corporation

Collaborators ^††

Investigators ^†

Principal Investigator:

Baxter BioScience Investigator

Baxter BioScience

Information Provided By

Baxter Healthcare Corporation

Verification Date

October 2006

First Received Date ^†

September 8, 2005

Last Updated Date

October 19, 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.